VANCOUVER, BC--(Marketwired - November 10, 2016) - According to a new series of reports on the U.S. market for anesthesia, respiratory and sleep management (ARS) devices by iData Research (www.idataresearch.com), the market is largely influenced by insurance policies, especially when it comes to durable devices governed under the durable manufacturer equipment (DME) realm. Beginning in January of 2016, the U.S. Congress dramatically cut reimbursement for home oxygen services by applying competitive rates in geographic areas that were previously excluded from competitive bidding. Some providers of home oxygen therapy have already started planning in order to stay operational in the face of such drastic shortfalls, which could result in the elimination of many of the critical services upon which patients have come to depend.
